In this article, we report a rare case of NBTE in a young patient with a long history of primary hypoparathyroidism and a family history of coagulation disorders.
Figure 1. The initial presentation of the patient.
Video 1. Intraoperative video. Minimally invasive mass excision.
The patient received enoxaparin sodium, until the resection of the vegetation. Via right mini-thoracotomy, the masses ( Figure 2), one at the anterior leaflet, and two at the posterior leaflet were minimally invasively resected (Video 1). Postoperatively, mitral valve functions returned to normal. The masses were 1¥0, 7¥0, and 5 mm, rough, white-yellow fibromyxoid tissue pieces that were calcified and organized fibrinoid vegetations ( Figure 3). Gram staining revealed no leukocytes or microorganisms and the culture result was negative. Based on these findings, the preliminary diagnosis of NBTE was confirmed. Postoperatively, the patient was scheduled for 15 sessions of left upper and lower extremity range of motion, proprioceptive neuromuscular facilitation, and muscle strengthening exercises. Her neuromotor functions improved and she still continues to take calcitriol and calcium without any complaints.
Figure 2. Endoscopic views of the masses on the atrial side of the mitral valve.
Figure 3. The microscopy of the extracted fibrinoid-thrombotic mass. (H&E, ¥0.9 and ¥7.8).
The diagnosis of NBTE can be difficult, as it often presents with similar symptoms to other conditions such as infective endocarditis and atherosclerotic disease. Transesophageal echocardiography can be used to evaluate valve lesions and determine the underlying etiology, if there is a clinical suspicion.[1] However, imaging tools are unable to distinguish between sterile and infective vegetations. A definitive diagnosis can be made through a histological examination.[3]
There is a known association between NBTE and hypercoagulable states, such as primary antiphospholipid syndrome, malignancy, burns, and sepsis.[2] The antinuclear antibodies (ANA), extractable nuclear antigens (ENA), anti-double stranded deoxyribonucleic acid (anti-dsDNA), rheumatoid factor, and anticardiolipin antibodies were also investigated to rule out any underlying autoimmune disease.[1] To assess hypercoagulable state, an extended coagulation screening and clotting factor assay should be performed, including prothrombin time, partial thromboplastin time, fibrinogen, thrombin time, D-dimer, and cross-linked fibrin degradation products.[1] In our case, the patient had a history of thrombosis in the family and was found to have the ACE gene D/D genotype, which is associated with an increased risk of thrombotic events.[4] A total body computed tomography (CT) scan revealed no evidence of cancer.
Hypercalcemia is also thought to be a potential contributing factor to NBTE. Calcium is known to cause vasoconstriction, activate multiple clotting factors, and increase platelet aggregation, all of which can lead to thrombosis.[5] The patient had hypoparathyroidism and received calcium and vitamin D supplements. Calcium therapy itself, however, is not thought to predispose thromboembolism.[6]
The primary treatment for NBTE is addressing the underlying condition. Long-term anticoagulation therapy, specifically unfractionated or low-molecularweight heparin, has shown efficacy and low risk of intracerebral hemorrhage in previous studies.[1] Frequent monitoring is necessary to rule out recurrent embolism and ensure an adequate anticoagulation. Factors such as the patient's age, comorbidities, valvular dysfunction, and recurrent thromboembolic events should be considered for making decision for surgery. Our patient underwent surgery due to recurrent embolism, despite anticoagulation and an unknown etiology.
In conclusion, non-bacterial thrombotic endocarditis is a rare condition and difficult to diagnose due to its similarity to other conditions. The presence of hypercoagulable state and calcium disorders should be considered as potential contributing factors. Further research is needed to better understand the pathogenesis of non-bacterial thrombotic endocarditis and to develop effective diagnostic and treatment strategies.
Patient Consent for Publication: A written informed consent was obtained from the patient.
Data Sharing Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.
Author Contributions: Idea/concept, control/supervision: Ş.Ş., C.A.; Design, data collection and/or processing: T.E.; Analysis and/or interpretation, literature review, writing the article: T.E., N.D.; Critical review, references and fundings: G.A.
Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
Funding: The authors received no financial support for the research and/or authorship of this article.
1) Hurrell H, Roberts-Thomson R, Prendergast BD. Noninfective
endocarditis. Heart 2020;106:1023-9. doi: 10.1136/
heartjnl-2019-315204.
2) Şimşek-Yavuz S, Akar AR, Aydoğdu S, Berzeg-Deniz D,
Demir H, Hazırolan T, et al. Consensus report on diagnosis,
treatment and prevention of infective endocarditis by
Turkish Society of Cardiovascular Surgery (TSCVS),
Turkish Society of Clinical Microbiology and Infectious
Diseases (KLIMIK), Turkish Society of Cardiology (TSC),
Turkish Society of Nuclear Medicine (TSNM), Turkish
Society of Radiology (TSR), Turkish Dental Association
(TDA) and Federation of Turkish Pathology Societies
(TURKPATH) cardiovascular system study group. Turk
Gogus Kalp Dama 2020;28:2-42. doi: 10.5606/tgkdc.
dergisi.2020.01954.
3) Eiken PW, Edwards WD, Tazelaar HD, McBane RD, Zehr KJ.
Surgical pathology of nonbacterial thrombotic endocarditis
in 30 patients, 1985-2000. Mayo Clin Proc 2001;76:1204-12.
doi: 10.4065/76.12.1204.
4) Vaughan DE. Fibrinolytic balance, the renin-angiotensin
system and atherosclerotic disease. Eur Heart J 1998;19
Suppl G:G9-12.